Niacin
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Dyslipidemia Medications (Misc. ) | Niacin | 250mg PO Q24H, titrate to 500mg PO Q8H | Administer Anytime During HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 123 | 12 | 0.5-1 | N/A | <20 | N/A | N/A | Minimal (high flux) |
References:
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00627
- Reiche I, Westphal S, Martens-Lobenhoffer J, Tröger U, Luley C, Bode-Böger S. Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. Nephrology, dialysis, transplantation (official publication of the European Dialysis and Transplant Association - European Renal Association) 2011; 26(1), 276-82.